Eucure (Beijing) Biopharma Co., Ltd
12
1
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
90.9%
+4.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
Role: lead
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
Role: lead
A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma
Role: lead
A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors
Role: lead
A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors
Role: lead
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Role: lead
Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma
Role: lead
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
Role: lead
A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC
Role: lead
A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors
Role: lead
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Role: lead
A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies
Role: lead
All 12 trials loaded